Split-dose technique for FDG PET/CT-guided percutaneous ablation: A method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness

Radiology

Volumn 268, Issue 1, 2013, Pages 288-295

  Ryan, E Ronan ^a   Sofocleous, Constantinos T ^a   Schöder, Heiko ^a   Carrasquillo, Jorge A ^a   Nehmeh, Sadek ^a   Larson, Steven M ^a   Thornton, Raymond ^a   Siegelbaum, Robert H ^a   Erinjeri, Joseph P ^a   Solomon, Stephen B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FLUORODEOXYGLUCOSE F 18; PREDNISONE;

ADRENAL TUMOR; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CRYOABLATION; ELECTROPORATION; ENDOMETRIUM CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG CANCER; LUNG TUMOR; MALE; MELANOMA; METASTASIS; MICROWAVE THERAPY; PANCREAS CANCER; PLEURA EFFUSION; PNEUMOTHORAX; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; RELIABILITY; SARCOMA; THERAPY EFFECT; TUMOR ABLATION; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CATHETER ABLATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84879915060     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121462     Document Type: Article

References (33)

1. Solomon SB, Silverman SG. Imaging in interventional oncology. Radiology 2010;257(3): 624-640.
2. Venkatesan AM, Kadoury S, Abi-Jaoudeh N, et al. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology 2011;260(3): 848-856.
3. Ayav A, Germain A, Marchal F, et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg 2010;200(4):435-439.
4. Kim KW, Lee JM, Klotz E, et al. Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol 2011;196(5):W565-W572.
5. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (. 2 and , 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 2010;195(3):758-765.
6. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006;59(3):432-441.
7. Meloni MF, Andreano A, Franza E, Passamonti M, Lazzaroni S. Contrast enhanced ultrasound: should it play a role in immediate evaluation of liver tumors following thermal ablation? Eur J Radiol 2012;81(8):e897-e902.
8. Vilar VS, Goldman SM, Ricci MD, et al. Analysis by MRI of residual tumor after radiofrequency ablation for early stage breast cancer. AJR Am J Roentgenol 2012; 198(3):W285-W291.
9. Deandreis D, Leboulleux S, Dromain C, et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 2011; 258(1):270-276.
10. Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H. 18F-FDG PET/ CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med 2010;51(12):1833-1840.
11. Okuma T, Okamura T, Matsuoka T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med 2006;20(2):115-121.
12. Liu ZY, Chang ZH, Lu ZM, Guo QY. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful? Chin Med J (Engl) 2010;123(13):1690-1694.
13. Schoellnast H, Larson SM, Nehmeh SA, Carrasquillo JA, Thornton RH, Solomon SB. Radiofrequency ablation of non-smallcell carcinoma of the lung under real-time FDG PET CT guidance. Cardiovasc Intervent Radiol 2011;34(Suppl 2):S182-S185.
14. Sainani NI, Shyn PB, Tatli S, Morrison PR, Tuncali K, Silverman SG. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation? J Vasc Interv Radiol 2011;22(3):354-360.
15. Eng J. Sample size estimation: how many individuals should be studied? Radiology 2003;227(2):309-313.
16. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002; 132(4):605-611; discussion 611-612.
17. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003; 10(4):338-347.
18. Pua BB, Sofocleous CT. Imaging to optimize liver tumor ablation. Imaging Med 2010; 2(4):433-443.
19. Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013;36(1):166-175.
20. Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology 2008; 249(1):364-374.
21. Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol 2012;19(13): 4262-4269.
22. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008;179(4):1277-1281; discussion 1281-1283.
23. Lokken RP, Gervais DA, Arellano RS, et al. Inflammatory nodules mimic applicator track seeding after percutaneous ablation of renal tumors. AJR Am J Roentgenol 2007;189(4):845-848.
24. Solomon SB. Can imaging be used to assess treatment success after ablation of renal tumors? Nat Clin Pract Urol 2008;5(12):642-643.
25. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43(1):189-204.
26. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC cancer staging manual 7th ed. New York, NY: Springer-Verlag, 2010.
27. Duncan JR, Balter S, Becker GJ, et al. Optimizing radiation use during fluoroscopic procedures: proceedings from a multidisciplinary consensus panel. J Vasc Interv Radiol 2011;22(4):425-429.
28. Cerqueira MD, Lawrence A. Nuclear cardiology update. Radiol Clin North Am 2001;39(5):931-946, vii-viii.
29. Ryan ER, Thornton RH, Sofocleous CT, et al. PET CT guided interventions: personnel radiation dose. Cardiovasc Intervent Radiol 2012 Nov 15. [Epub ahead of print]
30. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. RadioGraphics 2008;28(2):379-390; discussion 390-392.
31. la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncol 2011;13(8):806-819.
32. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39(7):1302-1305.
33. Thie JA, Hubner KF, Smith GT. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol 2002;4(3):238-244.